Keyphrases
Infliximab Biosimilar
66%
Etanercept Biosimilar
66%
Transdermal Opioids
66%
National Cohort Study
66%
Potentially Inappropriate Medication
66%
COVID-19
66%
Improved Survival
66%
Late-stage Cancer
66%
Hospitalized Patients
66%
Safety Database
66%
Remdesivir
66%
Standard of Care
55%
Molecular Tumor Board
50%
Odds Ratio
33%
30-day Mortality
33%
Mechanical Ventilation
33%
Confidence Interval
33%
Moderate to Severe
22%
Severe Coronavirus Disease 2019
22%
End-stage Cancer
16%
Druggability
16%
Omicron BA.2
11%
Anti-CD20 Therapy
11%
Logistic Regression Analysis
11%
Nationwide Cohort
11%
Inverse Probability
11%
Population-based
11%
Electronic Data Capture
9%
Opioid Management
9%
Early Treatment Discontinuation
8%
Physician Training
5%
Somatic Medication
5%
Medication List
5%
Interprofessional Approach
5%
IQVIA
5%
Rapid Dissemination
5%
Prescribing Appropriateness
5%
Prescribing Quality
5%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Cohort Study
88%
SARS Coronavirus
66%
Polypharmacy
66%
Remdesivir
66%
Hematologic Malignancy
66%
Dexamethasone
66%
Coronavirinae
66%
Anticoagulant Agent
66%
Antivitamin K
66%
Atrial Fibrillation
66%
COVID-19 Vaccine
44%
Prevalence
33%
Cross-Sectional Study
33%
Psychotropic Agent
33%
Immune Deficiency
22%
Infection
22%
Mortality Rate
11%
Thromboembolism
10%
Transdermal Patch
8%
Dabigatran
5%
Cerebrovascular Accident
5%
Drug Utilization
5%
Brain Ischemia
5%
Bleeding
5%
Medicine and Dentistry
Personalized Medicine
66%
Antithrombotic
66%
Vitamin K Antagonist
66%
Cancer Staging
66%
Targeted Therapy
66%
Atrial Fibrillation
66%
Malignant Neoplasm
50%
Neoplasm
50%
Clinical Trial
33%
Anticoagulant Therapy
24%
Prostate Cancer
16%
Tumor Biopsy
16%
Lung Cancer
16%
Biological Marker
16%
Molecular Profiling
16%
CHA2DS2-VASc Score
12%
Thromboembolism
12%
Dabigatran
6%
Patient Characteristics
6%
Bleeding
6%
Brain Ischemia
6%
Apoplexy
6%